Mira Keyes, MD FRCPC
University of British Columbia (UBC)
Active Staff: Radiation Oncologist
British Columbia Cancer Agency (BCCA) – Vancouver Centre *
Head, BCCA Prostate Brachytherapy Program BC Cancer Agency (BCCA)
Active Clinical Staff – Vancouver General Hospital (VGH)
Hospital Authority: Provincial Health Services
600 West 10th Avenue
Vancouver, BC V5Z 4E6
Phone: 604.877.6000 local 2660 Fax: 604.877.0505
Major Clinical Focus –
• Prostate Brachytherapy
• Genito-Urinary Oncology
• Breast Cancer
• Postgraduate Medical Education
• Patient Communication
• Medical Doctor (Medicine), University of Novi Sad, Yugoslavia, Serbia, 1986
• FRCPC Radiation Oncology, Royal College of Physicians of Canada, 1996
• Fellow of The Royal College of Physicians of Canada (Radiation Oncology), Vancouver Cancer Centre 1996-1997
• MCCEE, LMCC & FMGEMS, Part I and Part II, 1990-1991
• Resident (Gynecology and Obstetrics), Institute of Oncology, Medical School, University of Novi Sad, Yugoslavia, 1987-1989
• Graduate Studies in Clinical Pharmacology, Medical School, University of Novi Sad, Yugoslavia, 1988-1989
• ABS school of Brachytherapy, 1995
• ONCOTALK course in Communication 2009, 2010
Biographic Summary ( Background, Academic Interests and Activities, Clinical Activities )
Dr Keyes I one of the 4 founders of the Provincial BCCA Prostate Brachytherapy Program (1997). She served as a Prostate Brachytherapy Program Quality Assurance chair, (2003-2007), since 2007 she is the head of the program.
She served as a UBC Radiation oncology Residency Training Program Director form June 2001 to June 2006. From 2007-2012, she was a of the Royal College of Physicians and Surgeons of Canada member of the Examination Board in Radiation Oncology. At present, she is working on a national level as core member and founder for certification standards leading to a Royal College Diploma of Special Competence in Brachytherapy. From 2006-2009 she served as a UBC-BCCA REB (Research Ethics Board) board member. She is a member of BCCA provincial GU and Breast tumour Groups.
Her research interests include Prostate Brachytherapy outcomes, Quality Assurance, and translational research.
She has been an invites speaker for CARO (Canadian Association of radiation oncology), CBG ( Canadian Brachytherapy Group), ASTRO (American Society for Therapeutic Radiation Oncology), ABS ( American Brachytherapy Society) and Seattle Prostate Institute Advanced Brachytherapy Course,
1. Keyes M, Morris WJ, Spadinger I, Araujo C, Cheung A, Chng N, et al. Radiation oncology and medical physics quality assurance in British Columbia Cancer Agency’s Provincial Prostate Brachytherapy Program. Brachytherapy (in press) 2012.
2. Keyes M, Spadinger I, Liu M, Pickles T, Pai H, Hayden A, et al. Rectal toxicity and rectal dosimetry in low-dose-rate iodine-125 permanent prostate implants: A long-term study in 1006 patients. Brachytherapy, 2012, 11, 3, 199-208.
3. Keyes M, Miller S, Moravan V, Pickles T, McKenzie M, Pai H, et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: Long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1023-32.
4. Keyes M, Miller S, Moravan V, Pickles T, Liu M, Spadinger I, et al. Urinary symptom flare in 712 (125)I prostate brachytherapy patients: Long-term follow-up. Int J Radiat Oncol Biol Phys. 2009 Feb 9.
5. Keyes M, Schellenberg D, Moravan V, McKenzie M, Agranovich A, Pickles T, et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve? Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):825-34.
6. Morris WJ, Keyes M, Palma D, Spadinger I, McKenzie MR, Agranovich A, et al. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. Urology. 2009 Apr;73(4):860,5; discussion 865-7.
7. Grimm PD, Billiet I, Bostwick DG, Dicker A. P., Frank SJ, Immerzeel J, Keyes M, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. results from the prostate cancer results study group. BJU Int. 2012;109(supp 1):22-9.
8. Pugh TJ, Keyes M, Barclay L, et al. Sequence variant discovery in DNA repair genes from radiosensitive and radiotolerant prostate brachytherapy patients. Clin Cancer Res 2009;15:5008-5016.
* The British Columbia Cancer Agency (BCCA)-Vancouver Centre (VC) is the largest academic cancer centre for the BCCA, located in downtown Vancouver and treating about one third of the radiation oncology cancer patients in the Province of BC. Over 4360 cancer patients are seen each year in the radiation oncology department. There are 20 Radiation Oncology (RO) physician faculty with full disease site specialization and clinical programs of excellence, 2 General Practice (Internist) Oncology Physicians, 3 Clinical Fellows and 10 RO residents. The BCCA-Vancouver Centre also has 17 physicists and a graduate training program in physics, 15 nurses, >60 radiation therapists clerks, secretaries and many others within radiation oncology. General capabilities include 9 Linacs (including Truebeam), 1 cobalt, VMAT (first developed in the BCCA-VC), IMRT, SBRT, IGRT, HDR and LDR brachytherapy suites, and Protons (at the TRIUMF centre). The Vancouver Centre radiation oncology department conducts all levels of research (basic, translational, clinical, population), and is the main educational institution in BC for the training of graduate (residents) and undergraduate (medical) students. The interdisciplinary Radiation Oncology team is part of the even larger multidisciplinary and provincial teams.